Algeos secure £900K GCC contract to supply life-saving products to local agents, distributors and hospitals in the Middle East
Algeos, a leading UK’s manufacturer and distributor of medical materials and technology to the podiatry, rehabilitation and orthopaedic markets, has secured a £900K GCC contract to supply products across the Middle East.
Image – (L) Max Sheridan, with Mustafa Mukbil, and the clinical team from the Middle East.
This includes diabetic footwear, orthotic and prosthetic materials, foot orthotics and other consumables that improve patients lives which will be distributed to local agents, distributors and hospitals across the Middle East.
The firm has been announced as the UK provider of diabetic footwear products to six GCC member states – the United Arab Emirates, Kingdom of Bahrain, Kingdom of Saudi Arabia, Sultanate of Oman, State of Qatar and the State of Kuwait.
The awarding of this GCC contract is a result of Algeos’ focus on support, prevention and changing lives, which it not only delivers through its work with the NHS, private practice and hospitals across the UK, but also its national standing in the podiatry, rehabilitation and orthopaedic sector.
Diabetes is a rapidly growing disease that is affecting people worldwide, particularly due to the rise in unhealthy lifestyles and increased risk factor levels. The Middle East has seen a spike in the occurrence of diabetes and the ulceration of the diabetic foot. Algeos’ products can enable diagnosis, prevention and life-saving solutions to prevent diabetic foot ulcers across a number of hospitals in the six GCC states.
Algeos has also provided expert training to a number of Saudi Arabian clinicians on a varied range of products, including the Voxelcare VXC3DP Filament Cube printing unit.
Max Sherridan, managing director, said:
“It’s been a team effort to ensure we were successful and have collaborated with our local partners in the regions to ensure that Algeos’ range of products are the preferred choice of clinicians in the Middle East.
“We look forward to supporting our partners and clinicians to ensure patient outcomes are maximised as part of this tender win.”
Mustafa Mukbil, business manager at Zimmo Co., added:
“My team and I are very grateful to Max Sheridan and the Algeos team. Algeos has been very impressive, as has the country and the people we have met during our time visiting the warehouse and surveying the products. I couldn’t recommend working with Algeos enough.
“The solutions Algeos provides are unlike anything we have ever seen before. Algeos’ items are perfect and of the highest quality, and we are looking forward to continuing to work with Max and Algeos more in the future.”
With 140 years of technological expertise and knowledge, Algeos has big ambitions to grow in the next three years, breaking into untapped markets, generating profitable growth and retaining its status as an industry leader while continuing to develop its sales in the Middle East and help hospitals in the region cope with the influx of diabetic patients.
For more information about Algeos, visit the website and follow Facebook, Twitter and LinkedIn
